Di-Pal-MTO
Di-Pal-MTO is a palm oil-based lipid produced by combining the anticancer agent mitoxantrone (MTO) with palmitoleic acid. When nanoparticles of mono-Pal-MTO and di-Pal-MTO are combined in a molar ratio of 1:1, they show effective siRNA cell delivery and enhance anticancer activity[1].
Product Specifications
CAS Number
[1349197-90-5]
UNSPSC
12352005
Target
Liposome
Type
Oligonucleotides
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/di-pal-mto.html
Purity
98.37
Solubility
DMSO : 10 mg/mL (ultrasonic)
Smiles
CCCCCC/C=C\CCCCCCCC(OCCNCCNC1=C2C(C(C3=C(O)C=CC(O)=C3C2=O)=O)=C(C=C1)NCCNCCOC(CCCCCCC/C=C\CCCCCC)=O)=O
Molecular Formula
C54H84N4O8
Molecular Weight
917.27
References & Citations
[1]Rae Sung Chang, et al. Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA. Biomaterials. 2011 Dec;32 (36) :9785-95.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Oligonucleotides
Clinical Information
No Development Reported
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15146901 1 Vial
Lentiviral human ARF6 shRNA (UAS) - Lentiviral human ARF6 shRNA (UAS, GFP) (100)
Sign In for Pricing
View Details 
67005141 1x 10^6 Cells / 1.0 mL
RNU1P3 CRISPR Knock Out 293T Cell Line (Human)
Sign In for Pricing
View Details